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DObjective: The results of mitral repair for complex Barlow valves are adequate and support earlier intervention.
It is unknown whether these results are reproducible in the context of minimally invasive surgery via right
minithoracotomy.
Methods: We randomized patients with Barlow mitral disease (bileaflet prolapse) to have conventional open
repair via median sternotomy (MS group) or minimally invasive (MI group) repair. Repair was done using
polytetrafluoroethylene chordal reimplantation for both leaflets. In the MI group, we adopted right minithora-
cotomy, peripheral cannulation, external aortic clamping, and surgery under direct vision.
Results: Both groups comprised 70 patients. The operative and the cardiopulmonary bypass times were signif-
icantly longer in the MI group (P ¼ .003 and P ¼ .012). Mitral repair was successful in 98.5%MI patients and
100%MS patients. Operative mortality was comparable. The mean mechanical ventilation time, intensive care
unit stay, and hospital stay were lower in the MI group (P ¼ .014, P ¼.02, and P ¼ .03,). Mean pain score was
lower in the MI group at postoperative days 2 and 4. At follow-up, the freedom from moderate (2þ) or severe (3þ
or 4þ) mitral regurgitation was 98% versus 97% (P¼ .9). Two patients underwent reoperation (1 in each group)
for late failure of repair. The Kaplan–Meier analysis confirmed these results.
Conclusions: Our data indicate that the optimal standard-of-care results of mitral repair for complex disease
(Barlow) are reproducible in the minimally invasive settings through right minithoracotomy and direct vision.
The minimally invasive technique can be proposed for complex mitral disease and early referral of these patients
can be encouraged. (J Thorac Cardiovasc Surg 2011;142:77-83)Barlow disease, also referred to as bileaflet prolapse, is con-
sidered to be a more generalized disease of the valve than
other forms of mitral valvular degeneration1 and is believed
to carry a different outcome after repair for severe mitral re-
gurgitation (MR). However, the surgical experience has
consistently grown in past decades and recent reports
have suggested that the results of the repair of Barlow
valves may be similar to those obtained for simpler mitral
conditions (fibroelastic deficiency, single-scallop pro-
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The Journal of Thoracic and Cplasty, and chordal shortening have been associated with
MR recurrence in patients with Barlow disease. Excellent
results have been obtained with bileaflet resection and pos-
terior sliding plasty plus ring annuloplasty3 or chordal reim-
platation for both leaflets.
A variety of technical solutions have been proposed for
the performance of minimally invasive surgery of the mitral
valve (use of the endoclamp or an external aortic clamp,
direct vision or video-assisted surgery, robotic or direct-
hand operation).Whichever the case, any less invasive strat-
egy to repair the mitral valve entails a greater surgical
complexity than open surgery. Standard-of-care mitral re-
pair using the totally videoscopic approach is indeed repro-
ducible4,5; however, few specific data on patients with
Barlow valve are available in the published reports. With
the present randomized trial we sought to compare the
feasibility, the operative results, and the follow-up out-
comes (recurrence of MR and need for mitral reoperation)
among patients undergoing mitral repair for Barlow disease
using either the median sternotomy approach or a less inva-
sive strategy through a right minithoracotomy, peripheral
cannulation, and direct vision. Thus, the reproducibility of
standard-of-care mitral repair is tested in the minimally
invasive settings.ardiovascular Surgery c Volume 142, Number 1 77
Abbreviations and Acronyms
AF ¼ atrial fibrillation
CPB ¼ cardiopulmonary bypass
MI group ¼ minimally invasive treatment group
MR ¼ mitral regurgitation
MS group ¼ median sternotomy treatment group
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Patient Selection and Study Design
Starting in January 2006, we prospectively selected patients according
to the following criteria:
 Patients had to have isolated, severe MRwith indication to undergo elec-
tive reparative surgery on the basis of the current guidelines.6 Patients
with associated coronary disease, other more than mild valvular disease,
congenital heart defects, and aortic diseasewere excluded from the study.
Indication for concomitant ablation of atrial fibrillation (AF) was not an
exclusion criterion.
 The etiology of MR had to be represented by Barlow disease (bileaflet
prolapse) of the mitral valve, as documented by preoperative echocardi-
ography.
 Patients were fully informed and willing to enter the study and had
signed an informed consent.
 The patients were free from any contraindication to right minithoracot-
omy and femoral cannulation and were facing their primary cardiac op-
eration. Patients affected by functional secondary tricuspid regurgitation
(grade>mild) were excluded, in view of their advanced disease and
prognosis distinct from that of patients with isolated MR.7
The aim of the present investigation was to analyze the clinical out-
comes associated with different routes of access to the mitral valve, rather
than the results of an established repair technique. The study design relied
on preoperative ultrasound imaging to differentiate the patients affected
by Barlow disease of the mitral valve from those carrying MR owing to
other causes. The finding of hoodlike bulging of different portions of
the anterior leaflet plus multiple bulging posterior scallops with excess tis-
sue and prolapse was referred to as Barlow valve. In the present article, the
term ‘‘bileaflet prolapse’’ identifies the same condition described above
and will be interchangeably used with the term ‘‘Barlow valve.’’ The in-
volvement of both leaflets in the disease process was an obligatory crite-
rion to define Barlow disease. In the event of such findings at transthoracic
echocardiography, preoperative transesophageal echocardiography was
used to confirm the diagnosis as part of the study protocol. After inclusion,
patients were randomized with the aid of a computerized algorithm to re-
ceive mitral valve repair via either the minimally invasive approach with
right minithoracotomy (MI group) or via conventional full median sternot-
omy (MS group). In both groups, mitral repair was the first objective of
the surgical treatment. To reduce the probability of bias, we started the
present investigation after our surgical team had reached a good mastery
of the minimally invasive technique and of the related technologies. The
study was planned on the basis of historical data from the GVM electronic
database concerning patients subjected to conventional mitral repair for
bileaflet prolapse. A sample size calculation indicated that 60 observations
per study group were adequate to detect with a 90% power a statistically
significant difference, if any, for the following study end points: operative
mortality, occurrence of at least 1 postoperative morbidity (among revi-
sion for bleeding, myocardial infarction, renal failure, neurologic compli-
cations, wound infection, and femoral complications), and recurrent
moderate-to-severe MR within the 12-month follow-up. The intention-
to-treat methodology was used.78 The Journal of Thoracic and Cardiovascular SurgeThe present randomized trial was conducted within 2 institutions (Villa
Azzurra Hospital, Rapallo, Italy, and Anthea Hospital, Bari, Italy) pertain-
ing to the GVM Hospitals of Care and Research Group. The local review
board approved the study protocol. The present clinical trial conforms to
the principles enunciated in the Helsinki declaration and the CONSORT
statement (available online at http://www.consort-statement.org). This
study was sponsored neither fully nor in part, and all the authors had
complete freedom of investigation. This investigation was not designed
to evaluate the performance of any specific medical device.
Study End Points
 Feasibility of successful mitral repair for Barlow disease (bileaflet pro-
lapse) via right minithoracotomy (rate of conversion to median sternot-
omy, rate of conversion to valve replacement).
 Operative results in the study groups (mortality, perioperative complica-
tions, postoperative course, and postoperative pain as assessed by a visual
analogic scale).
 Midterm follow-up: rates of overall survival, recurrent MR-free survival,
and reoperation-free survival.Surgery
In the MI group, the surgical technique entailed a minimally invasive
access to the mitral valve via a 4- to 5-cm right anterolateral minithoracot-
omy in the inframammary groove (third intercostal space, working port).
An instrument port was done at the fifth to seventh intercostal space at
the midaxillary line for cardiotomy suction and carbon dioxide insufflation.
The procedure was carried out using long-shafted instruments through the
minithoracotomy incision and under direct vision. Selective bronchial
intubation and single lung ventilation were required. The pericardium
was incised parallel to the phrenic nerve and stay sutures were placed. After
the adequacy of exposure was confirmed, cardiopulmonary bypass (CPB)
was established. The venous drainage was obtained with cannulation of
the superior vena cava percutaneously through the right internal jugular
vein (FEMII016AS 16F cannula; Edwards Lifesciences Research Medical
Inc,Midvale, Utah) and of the common femoral vein via a right or left groin
incision (QuickDraw QD22 femoral–atrial venous cannula; Edwards Life-
science Research Medical Inc). Arterial inflow was provided with direct
cannulation of the ascending aorta. In case of technical difficulties and in-
ability to adequately dominate the ascending aorta, the common femoral
artery was cannulated (Seldinger technique) using the Straight Tip 23F
with Autoincisor Introducer (Edwards Lifescience Research Medical
Inc). The ascending aorta was crossclamped externally using a Chitwood
clamp (Chitwood; Scanlan International, St Paul, Minn). The endoclamp
device was not used in our practice. A cardioplegia needle was inserted
in the ascending aorta and secured with tourniquets (9F needle; Maquet
Cardiopulmonary AG, Hirrlingen, Germany). After cardiac arrest using
cold antegrade blood cardioplegia, left atriotomy was performed and the
mitral valve was accessed.
In the MS group, conventional full median sternotomy with ascending
aortic and bicaval cannulation was used. A vacuum-assisted venous drain-
age was used in both groups (digital regulation by AMVEX 100 device;
Amvex Corp, Richmond Hill, Ontario, Canada). A phosphorylcholine-
coated circuit with low priming volume was used routinely in all cases.
The same concepts and standardized surgical protocols for mitral valve
repair were adopted in both study groups. Rather than quadrangular resec-
tion with sliding or edge-to-edge approximation, we routinely adopted
artificial chordal polytetrafluoroethylene reimplantation (Gore-Tex; W. L.
Gore & Associates, Inc, Flagstaff, Ariz) for both leaflets. All mitral repair
procedures were completed with semirigid ring annuloplasty. After com-
pletion of the procedure and weaning from CPB, the continence of the
valve was checked by transesophageal echocardiography. We indicated
concomitant ablation of AF in patients with paroxysmal or persisting AF
and having a left atrial diameter not exceeding 60 mm (parasternal longry c July 2011
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Daxis view). Concomitant ablation of AF was performed using a saline-
irrigated tip disposable unipolar radiofrequency device. The ablation was
performed after completion of mitral repair. It consisted of electrical isola-
tion of the 4 pulmonary vein ostia and creation of a ‘‘mitral line’’ connect-
ing with the mitral annulus in the region of P3.
Operative mortality was defined as all-cause death within 30 postoper-
ative days. Perioperative neurologic complications (stroke or transient is-
chemic attack) were defined as a new neurologic deficit or coma, which
became apparent on awakening from the anesthesia. Postoperative renal
failure was defined as the increase of the serum creatinine level greater
than 2 mg/dL with respect to the preoperative value. Postoperative pain
was assessed by the administration of a visual analog scale (range:
0 ¼ no pain to 10 ¼ maximum pain) to all awake patients at the second,
fourth, and sixth postoperative days. As a routine protocol, in the absence
of contraindications, all patients enrolled in this study received intravenous
ketorolac 30 mg each day until the fourth postoperative day. Subsequently,
they received oral indomethacin, 50 mg twice a day. We adopted as a crite-
rion for extubation the maintenance of the following blood gas parameters
after disconnection from the ventilator: arterial oxygen tension greater than
80 mm Hg (arterial oxygen saturation>95%), arterial carbon dioxide ten-
sion 32 to 48 mm Hg, and pH 7.32 to 7.48. Contraindications to extubation
were recent stroke, hemodynamic instability, and mediastinal bleeding.
Standardized criteria were also applied to decide the intensive care unit
and hospital discharge. The postoperative data were managed in compli-
ance with the current guidelines.8
Follow-up
Follow-up was conducted by outpatient visits 1 month after surgery, at
the sixth and twelfth postoperative months, and every year thereafter. The
visit included physical examination, surface electrocardiogram, and trans-
thoracic echocardiogram. With respect to the study end points, recurrent
MR was defined as moderate or severe (3þor 4þ) MR as demonstrated at
any follow-up echocardiogram. To the purposes of MR assessment, we
adopted the current criteria as per the American College of Cardiology/
American Heart Association guidelines (mild, 1þ; moderate, 2þ; severe, 3þ
or 4þ). Mitral reoperation was defined as reoperation on the mitral valve
owing to late failure of repair during the follow-up. Conversion to valve
replacement owing to failed repair during the primary operation was not
considered as a mitral reoperation. Recurrent MR and mitral reoperation
were considered as mitral events during the follow-up. Patients whoFIGURE 1. Study design. MI group, Minimally invasive treatm
The Journal of Thoracic and Creceived concomitant AF ablation entered a specific follow-up program
consisting of periodic Holter electrocardiographic tracings to evaluate
the rhythm over time.
Statistical Methods
All data were collected prospectively and entered in a computerized
database by surgical assistants at the time of patients’ discharge from the
hospital. Continuous data are reported as mean  standard deviation and
categorical variables as percentages. Intergroup comparison was conducted
using the c2 test and the 2-tailed Student t test for categorical and contin-
uous variables, respectively. Survival analysis was performed according to
the Kaplan–Meier method, and corresponding survival curves were built.
Kaplan–Meier analysis was performed for both overall survival and mitral
event-free survival. The date of the first echocardiogram demonstrating re-
current MR was considered as the date of event. The log–rank statistic was
used to compare the survival probabilities between groups. The alpha level
was .05. The statistical analysis was conducted using SPSS version 13.0 for
Windows (Statistical Package for Social Sciences; SPSS, Inc, Chicago, Ill).
The sample size calculation was done using the Power and Sample Size
Calculation Software version 3.0.14 for Windows.9RESULTS
The study design is reported in Figure 1. We screened
a total of 618 patients affected by isolated mitral valve dis-
ease; of these, 159 (25.7%) were given a diagnosis of Bar-
low disease according to the above echocardiographic
criteria. Nineteen patients refused to enter the study; thus,
we enrolled and randomized a final cohort of 140 individ-
uals. Both study groups comprised 70 patients. The baseline
characteristics of the study population are summarized in
Table 1.Operative Results
The overall operative time, the aortic crossclamp time,
and the CPB time were significantly longer in the MI group
(Table 2). The mean number of neochordae implanted perent group; MS group, median sternotomy treatment group.
ardiovascular Surgery c Volume 142, Number 1 79
TABLE 1. Baseline characteristics of the study groups
Characteristic MI group MS group P
Age (y) 53.2  10.4 54  10.1 .68
Sex (male/female) 41/29 43/27 .86
NYHA class III-IV 21 (30%) 19 (27%) .85
Preoperative AF (n) 16 (22.8%) 18 (25.7%) .84
Preoperative LVEF<50%
and>35% (n)
11 (15.7%) 12 (17.1%) .99
Preoperative LVEF<35% (n) 2 (2.8%) 2 (2.8%) —
MI group, Minimally invasive treatment group; MS group, median sternotomy treat-
ment group; NYHA, New York Heart Association; AF, atrial fibrillation; LVEF, left
ventricular ejection fraction.
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was performed in any case. Conversion of the procedure to
mitral replacement was required in 1 case. This was due to
failed repair that became evident at transesophageal
echocardiography after weaning from CPB. Prosthetic
replacement could be carried out by minithoracotomy. Con-
comitant ablation of AF was performed in 11 patients in the
MI group and in 12 patients in theMS group (no statistically
significant difference). Causes of operative mortality were
stroke in 1 case, adult respiratory distress syndrome in 1
case, and postoperative low output in 1 case. The average
mechanical ventilation time was significantly shorter in
the MI group. The mean pain scores were significantly
lower in the MI group at all time points (second, fourth,
and sixth postoperative days). The shorter ventilation time
observed in the MI group is also reflected by the earlierTABLE 2. Intraoperative and early postoperative results
Characteristic M
CPB time (min) 139
Aortic crossclamp time (min) 92
Operative time (min) 296
Conversion to mitral replacement (n) 1
Average number of prolapsing segments per patient 2.9
Average No. of neochordae per patient 5.4
Average No, of treated segments per patient 2.8
ICU stay (d) 2.1
Mechanical ventilation time (d) 1.2
Revision for bleeding* (n) 4
Overall bleeding (mL/m2) 759
Patients transfused with blood products (n) 19
Hospital stay (d) 8.6
Myocardial infarction* (n) 1
Postoperative renal failure* (n) 3
Neurologic complications* (n) 1
Femoral complications*,y (n)
Wound infection* (n)
Operative mortality (n) 2
Postoperative pain: 2nd day 2.8
Postoperative pain: 4th day 2.3
Postoperative pain: 6th day 1.5
MI group, Minimally invasive treatment group; MS group, median sternotomy treatment g
affected by each complication cited. yComplications at the level of the femoral vessels ca
80 The Journal of Thoracic and Cardiovascular Surgedischarge from the intensive care unit and from the hospital.
The rates of the remaining postoperative morbidity (renal
failure, neurologic complications, myocardial infarction,
bleeding, and bleeding-related morbidity) were comparable
between groups.Follow-up Results
Mean follow-up timewas 12.4 months. One patient in the
MS group was lost at follow-up; thus, the follow-up was
99% complete. One patient (MI group) died during the
follow-up owing to a noncardiac cause (car crash). Overall,
the outcome variables pertaining to study end point 3 were
comparable between the MI and the MS groups. Among the
surviving patients, the freedom from moderate or severe
MR was 97% in the MS group versus 98% in the MI group
(P¼ .9). One patient in each group had a reoperation on the
mitral valve owing to late failure of repair and symptoms of
heart failure. In both cases, valve replacement via median
sternotomy was performed. Thus, a total of 3 mitral events
(2 reoperations and 1 case of severe MR) were included in
the follow-up (Table 3).
The Kaplan–Meier curves for overall survival in the 2
study groups are reported in Figure 2: there was no statisti-
cal difference between the curves (P ¼ .86). Mitral event-
free survival was also comparable between the MS and
the MI groups (P ¼ .74) (Figure 3). Thus, time-to-event
analysis confirmed that the follow-up outcomes are compa-
rable between the study groups. Among the patients whoI group MS group P
 28 101  24 .012
 23.3 70  18 .02
 118 249  91 .003
(1.3%) 0 .8
 0.6 3.0  0.6 .89
 0.9 5.6  1.0 .53
 0.6 2.9  0.5 .77
 0.9 3.2  1.1 .02
 0.2 2.3  0.5 .014
(5.7%) 3 (4.3%) .99
 387 741  370 .63
(27.1%) 21 (30%) .85
 4.7 11.8  5.2 .03
(1.4%) 0 .99
(4.3%) 3(4.3%) —
(1.4%) 2 (2.8%) .99
0 — —
0 1 (1.4%) .99
(2.8%) 1 (1.3%) .99
 0.9 4.7  1.3 .001
 0.8 5.1  1.5 <.001
 0.4 3.1  0.9 .002
roup; CPB, cardiopulmonary bypass; ICU, intensive care unit. *Number of patients
nnulation (pseudoaneurysm formation, bleeding, revision of the groin incision).
ry c July 2011
TABLE 3. Follow-up results
Characteristic MI group MS group P
End-of-follow-up overall mortality 3 (4.3%) 1 (1.4%) .61
Mild MR (n) 1 2 .99
Moderate or severe MR (n) 2 1 .61
Mitral reoperation (n) 1 1 .99
MI group, Minimally invasive treatment group; MS group, median sternotomy treat-
ment group; MR, mitral regurgitation.
Speziale et al Acquired Cardiovascular Diseasereceived concomitant AF ablation, 72% and 75% (MI and
MS groups, respectively) were in stable sinus rhythm
at the last follow-up available (no statistically significant
difference).FIGURE 3. Kaplan–Meier survival curves: mitral event-free survival in
theMI and in the MS group during follow-up. Difference is not statistically
significant (log–rank). Number of patients at risk at each time point (5, 10,
15, 20, and 24 months) is reported below. MI group, Minimally invasive
treatment group; MS group, median sternotomy treatment group.
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The Third Adult Cardiac Surgical Database Report 2006
of the European Association for Cardio-Thoracic Surgery10
indicates that a total of 4491 isolated mitral valve operations
were performed in 2006 in the 18 contributor countries. The
database probably underestimates the real number of
operations performed. Additionally, it is limited by the im-
possibility to distinguish between patients operated on for
rheumatic disease versus those operated on for degenerative
disease and between patients who received mitral repair
versus those who received mitral replacement. However, it
is evident that mitral disease is one leading indication for
heart surgery. In the published series of mitral repair, theFIGURE 2. Kaplan–Meier survival curves: overall survival in the MI and
in the MS group during follow-up. Difference is not statistically significant
(log–rank). Number of patients at risk at each time point (5, 10, 15, 20, and
24 months) is reported below. MI group, Minimally invasive treatment
group; MS group, median sternotomy treatment group.
The Journal of Thoracic and Cproportion of individuals with Barlow disease, also referred
to as bileaflet prolapse, ranges between 15% and 25%. This
condition entails a myxoid appearance of the whole valve
and several factors contributing to incompetence, including
annular dilation, bileaflet prolapse, chordal elongation, ex-
cess tissue, and billowing. As such, the long-term outcome
of the repaired valves may be influenced by the progression
of the disease within the native leaflets. In the current era,
the results of mitral repair for complex disease are ap-
proaching those observed after repair for simpler degenera-
tive conditions (ie, isolated P2 prolapse), thanks to a deeper
knowledge of mitral pathophysiology and to standardized
surgical techniques,2 However, minimally invasive surgery
for the atrioventricular valves is becoming increasingly
popular. Robotic surgery has also been advocated in this in-
stance11; however, escalating costs and scarce reproducibil-
ity have confined this approach to little more than clinical
research. On the contrary, the right minithoracotomy ap-
proach with thoracic ports, long instruments, and peripheral
cannulation with or without videoscopic assistance is a clin-
ical reality and has proved to be safe and feasible.4,5,12
A large retrospective analysis of mitral repair operations
(rheumatic or degenerative disease) has indicated that the
results of the repair of myxomatous valves are excellent
and superior to those obtained for rheumatic valves.13 The
proportion of Barlow patients in the myxomatous valve
subgroups was not, however, available. Nonetheless, the
minimally invasive operations involve a higher level of
technical complexity. This is probably reflected by theardiovascular Surgery c Volume 142, Number 1 81
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The present randomized study was designed to ascertain
whether the results of minimally invasive mitral repair for
the complex bileaflet prolapse condition are comparable
with those obtained via median sternotomy.
In this articlewe report the early andmidterm results of this
trial. We selected a homogeneous study cohort to reduce as
much as possible the population bias, with particular atten-
tion to the mechanism ofmitral incompetence. Our data indi-
cate that the repair of the severely regurgitant Barlow valve is
feasible and reproducible through the minithoracotomy ac-
cess. Operative mortality and major morbidity were both
comparable between groups. There was only 1 case in the
MI group of obliged conversion tomedian sternotomy, owing
to inadequate exposure. In addition, the patients operated on
with the minimally invasive approach displayed the typical
advantages associated with the preservation of the sternal
bone and respiratory mechanics (shorter intubation time de-
spite a longer CPB time). The reduced pain scores observed
in the MI group are in touch with this element. These data
agree with previous findings, which underline the potential
of minimally invasive mitral surgery to facilitate the postop-
erative recovery.4,5 We could not demonstrate a statistically
different incidence of surgical wound complications
between the groups. However, a lesser surgical trauma and
the preservation of the sternal bone reduces the potential
for wound infection and dehiscence in the MI group.
Improvements in the ventilator weaning protocols may
further reduce the mechanical ventilation time. Besides the
cosmetic advantages, a more rapid postoperative recovery,
and reduced postoperative pain, the minimally invasive
operationmay behighly cost-effective owing to shorter inten-
sive care unit and hospital stays. However, such economic
benefits should beweighed against the higher costs of dispos-
able materials and specific instrumentation. A comparison
versus the MS group even under the economic profile may
be advisable. A formal cost-analysis to address these points
is expected in the current era, in which the management of
health care expenditures represents a growing ethical and
political problem.
In our practice, the MI group was characterized by a lon-
ger CPB time and aortic crossclamp time than the MS
group. Thus, we believe in the importance of an optimal
technique for myocardial protection in these patients and
the usefulness of biocompatible CPB circuits, aimed at re-
ducing the magnitude of CPB-related systemic inflamma-
tory response and end-organ damage.
Our follow-up data suggest that the incidence of mitral
events (including both recurrent MR and mitral reoperation)
is acceptable and similar between the study groups. However,
more follow-up data and long-term results are required inas-
much as inBarlow disease the spared valve tissue is abnormal
and prone to evolution. An intergroup difference in outcomes
related to end point 3 may appear over time. The role of an82 The Journal of Thoracic and Cardiovascular Surgeannuloplasty ring to improve the long-term results has been
definitely ascertained.13,14 The implantation of a ring was
a constitutive part of our standardized surgical technique. In
addition to ring annuloplasty, as an institutional policy we
routinely treated bileaflet prolapse with chordal
reimplantation without performing extensive leaflet
resections. Such strategy is aimed at increasing the
coaptation area and the coaptation line and at reducing the
extent of the prolapse by increasing the coaptation depth. A
recent prospective randomized trial has demonstrated that
the implantation of neochordae made of expanded
polytetrafluoroethylene achieves similar results compared
with scallop resection in the treatment of the prolapse of the
anterior leaflet.15As a collateral finding, we confirm previous
results16 that concomitant AF ablation is feasible during MI
mitral operations. The follow-up results (maintenance of si-
nus rhythm) were comparable between our groups.
The present data suggest that the MI technique is similar
to conventional surgery concerning the feasibility profile
and the operative and follow-up results. However, the re-
duced postoperative pain, facilitated recovery, and cosmetic
advantages support a more liberal application of the MI
technique. The short follow-up time does not allow us to
draw conclusions over the long-term results of mitral repair
in these groups, and this is an important limitation of the
present study. Nonetheless, inasmuch as our end points
are related to merely technical issues, the comparability in
mitral events at 1 year indicates that the clinical results of
state-of-the-art mitral valve repair can be reliably achieved
via the MI route.
Earlier referral for mitral valvular disease amenable to
repair has been an increasing practice in recent years, sup-
ported by enlarging surgical experience. Such tendency
may be further encouraged by the present data. The refer-
ring physicians should be aware that the advantages of early
standard-of-care mitral repair can be achieved at the price of
lesser surgical morbidity and a shorter postoperative course
if minimally invasive techniques are used. Such issues may
now deserve discussion in the context of interdisciplinary
meetings and guideline revision committees.References
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